Cell Point FY26 net profit falls to ₹6.35 lakh as revenue rises
Cell Point (India) Limited reported a net profit of ₹6.35 lakh for FY26, down from ₹226.15 lakh in the previous year, while revenue increased to ₹36,793.36 lakh. The Board approved the audited results and appointed M/s Sankaran and Krishnan as internal auditors for FY26-27. Statutory auditors issued an unmodified opinion on the financial results.
*this image is generated using AI for illustrative purposes only.
Cell Point (India) Limited reported a net profit of ₹6.35 lakh for the financial year ended March 31, 2026, a significant decline from ₹226.15 lakh in the previous year. Revenue from operations for the period rose to ₹36,793.36 lakh, compared to ₹32,470.58 lakh in FY25. The company's Board of Directors approved the audited financial results for the half year and year ended March 31, 2026 at a meeting held on May 27, 2026.
Financial Performance
The company's total revenue for FY26 stood at ₹36,851.73 lakh, up from ₹32,625.86 lakh in the previous year. Total expenses increased to ₹36,757.84 lakh from ₹32,579.08 lakh. Profit before tax for the year was ₹93.89 lakh, lower than the ₹281.41 lakh reported in FY25. The basic earnings per share (EPS) for the year dropped to ₹0.034 from ₹1.210 in the prior year.
For the half year ended March 31, 2026, the company reported a net loss of ₹12.73 lakh. Revenue from operations for this period was ₹19,098.82 lakh, while total expenses were ₹19,061.11 lakh.
Balance Sheet and Cash Flows
The company's total assets as of March 31, 2026, were ₹16,910.50 lakh, an increase from ₹13,815.82 lakh in the previous year. Shareholders' funds stood at ₹7,431.74 lakh, slightly up from ₹7,425.39 lakh. Long-term borrowings surged to ₹3,114.95 lakh from ₹89.82 lakh, while short-term borrowings increased to ₹4,595.77 lakh from ₹4,435.62 lakh.
Cash and cash equivalents decreased to ₹592.68 lakh from ₹644.26 lakh at the end of the previous year. Net cash generated from operating activities was ₹123.98 lakh, compared to a net usage of ₹68.85 lakh in FY25. The company invested heavily in fixed assets, with net cash used in investing activities totaling ₹2,753.17 lakh.
Board Approvals and Disclosures
The Board approved the appointment of M/s Sankaran and Krishnan, Chartered Accountants, as internal auditors for the financial year 2026-27. Additionally, the Board considered and approved related party transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure for the half year ended March 31, 2026, was submitted to the exchange.
The statutory auditors, M/s Rao and Kumar, issued an audit report with an unmodified opinion on the standalone financial results. The financial results were prepared in compliance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, and Regulation 33 of the SEBI Listing Regulations.
Historical Stock Returns for Cell Point
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.99% | +2.33% | 0.0% | -6.12% | -19.63% | -75.20% |
How will the surge in long-term borrowings impact the company's interest expenses and debt servicing capabilities in the coming fiscal year?
What specific fixed assets did the company invest in during FY26, and when are these investments expected to start contributing to profitability?
With cash and cash equivalents decreasing, does the company plan to raise additional capital or rely on further borrowing to fund its operations?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
